SCHEMBL3489421

SCHEMBL3489421

CC(C)(C)OC(=O)NC12CN(C(=O)OCc3ccccc3)CC(CF)(C1)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 2/20 0.41
SYK P43405 1/20 0.40
RORC P51449 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PDE4B Q07343 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
CTSL P07711 1/20 0.38
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CYP2C19 P33261 1/20 0.37
P2RX7 Q99572 1/20 0.37
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK3 Q15120 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14828963 0.83 SYK (0.46) SYKRORCMEN1KMT2APDE4B
SCHEMBL3489145 0.81 MEN1 (0.42) RORCMEN1KMT2ANPSR1HTT
SCHEMBL19748028 0.80 DPP8 (0.46) DPP8DPP9SYKRORCMEN1
SCHEMBL8569029 0.79 PIK3R1 (0.45) SYKRORCMEN1KMT2APDE4B
SCHEMBL30954928 0.78 SYK (0.42) SYKRORCMEN1KMT2APDE4B
SCHEMBL30994176 0.78 P2RX7 (0.42) DPP8DPP9SYKMEN1KMT2A
SCHEMBL19718197 0.78 MEN1 (0.46) SYKMEN1KMT2ANPSR1HTT
SCHEMBL15082007 0.78 DPP8 (0.40) DPP8DPP9SYKRORCMEN1
SCHEMBL1467693 0.77 MEN1 (0.44) SYKRORCMEN1KMT2APDE4B
SCHEMBL27929780 0.77 MEN1 (0.44) SYKRORCMEN1KMT2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056497-A1 AMIDE DERIVATIVE REN, AGTR1, AGTR2 DPP8 1012/4885DPP9 833/4885SYK 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.